Molecular pathogenesis of Philadelphia chromosome negative myeloproliferative disorders
about
HSP90 and HSP70: Implication in Inflammation Processes and Therapeutic Approaches for Myeloproliferative NeoplasmsJAK2 V617F in myeloid disorders: what do we know now, and where are we headed?JAK2 inhibitors do not affect stem cells present in the spleens of patients with myelofibrosis.Sequential treatment of CD34+ cells from patients with primary myelofibrosis with chromatin-modifying agents eliminate JAK2V617F-positive NOD/SCID marrow repopulating cells.Recent advances in the bcr-abl negative chronic myeloproliferative diseases.The orally bioavailable MDM2 antagonist RG7112 and pegylated interferon α 2a target JAK2V617F-positive progenitor and stem cells.Molecular approach to diagnose BCR/ABL negative chronic myeloproliferative neoplasms.Combination treatment in vitro with Nutlin, a small-molecule antagonist of MDM2, and pegylated interferon-α 2a specifically targets JAK2V617F-positive polycythemia vera cellsSpleens of myelofibrosis patients contain malignant hematopoietic stem cellsAdvances in the understanding and management of myeloproliferative disorders.Non ST-segment elevation myocardial infarction in patient with essential thrombocythemia.Genetic complexity of myeloproliferative neoplasms.Molecular basis and clonal evolution of myeloproliferative neoplasms.T cells from patients with polycythemia vera elaborate growth factors which contribute to endogenous erythroid and megakaryocyte colony formation.Understanding Splenomegaly in Myelofibrosis: Association with Molecular Pathogenesis.
P2860
Q26778548-53D79BFB-D33A-4603-B430-630BD74FC00BQ33341856-55356864-B56E-4615-B52D-C273EAB45C4DQ34471806-A733F30E-7364-446C-AE14-BF5BC9247BB3Q34541582-37D75C99-0771-483D-B309-435EBDC2EBE4Q35126938-B5D03826-3FC4-43D9-916B-3B6EC800B59EQ35743852-4763E1D0-DEAC-4261-9361-38FBBC09BD77Q36153557-86DEAD33-BFAC-4AF2-A468-FC9027143AF0Q36318162-A6D2F779-06C1-4FAB-9FA4-5FAD7C94EFB5Q36356466-8897A31C-56D7-4AC9-B2D0-0E7247A965FFQ36922481-951FA6AA-2A7A-4955-AA7E-CDCA0DB9F669Q37120080-6D1A63FE-D1E1-4C26-876F-0D441B68EC7CQ37255024-B1188C11-6C39-43CC-B58C-32386B856404Q42832535-3E7B1E66-5979-4F13-AFCD-89538C17D59DQ50929723-E9787D8F-4D02-4C5D-9477-7D0C3E46DE72Q51737052-7B2DC63B-1143-4A2E-9C8C-74D77938E199
P2860
Molecular pathogenesis of Philadelphia chromosome negative myeloproliferative disorders
description
2005 nî lūn-bûn
@nan
2005 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Molecular pathogenesis of Philadelphia chromosome negative myeloproliferative disorders
@ast
Molecular pathogenesis of Philadelphia chromosome negative myeloproliferative disorders
@en
Molecular pathogenesis of Philadelphia chromosome negative myeloproliferative disorders
@nl
type
label
Molecular pathogenesis of Philadelphia chromosome negative myeloproliferative disorders
@ast
Molecular pathogenesis of Philadelphia chromosome negative myeloproliferative disorders
@en
Molecular pathogenesis of Philadelphia chromosome negative myeloproliferative disorders
@nl
prefLabel
Molecular pathogenesis of Philadelphia chromosome negative myeloproliferative disorders
@ast
Molecular pathogenesis of Philadelphia chromosome negative myeloproliferative disorders
@en
Molecular pathogenesis of Philadelphia chromosome negative myeloproliferative disorders
@nl
P1433
P1476
Molecular pathogenesis of Philadelphia chromosome negative myeloproliferative disorders
@en
P2093
Radek C Skoda
P356
10.1016/J.BLRE.2004.02.002
P407
P577
2005-01-01T00:00:00Z